Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis
暂无分享,去创建一个
Alok Srivastava | Christine Chomienne | Biju George | B. George | K. Lakshmi | P. Balasubramanian | V. Mathews | C. Chomienne | S. David | A. A. Alex | S. Ganesan | Hamenth Kumar Palani | N. Balasundaram | A. Korula | A. Abraham | A. Srivastava | Ansu Abu Alex | Saravanan Ganesan | Nithya Balasundaram | Sachin David | Kavitha M. Lakshmi | Uday P. Kulkarni | P. N. Nisham | Anu Korula | Anup J. Devasia | Nancy Beryl Janet | Aby Abraham | Rose Ann Padua | Poonkuzhali Balasubramanian | Vikram Mathews | N. Janet | R. Padua | A. Devasia | U. Kulkarni | P. Nisham
[1] M. Gobbi,et al. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate , 2009, Leukemia.
[2] H. Ljunggren,et al. Escape from immune- and nonimmune-mediated tumor surveillance. , 2006, Seminars in cancer biology.
[3] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[4] Haiyoung Jung,et al. TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. , 2011, Immunology letters.
[5] M. Robin,et al. PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia , 2003, Nature Medicine.
[6] R. Doherty. Long term follow up , 1999, BMJ.
[7] T. Pelliniemi,et al. Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors. , 1995, Medical and pediatric oncology.
[8] G. Morgan,et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.
[9] L. Zitvogel,et al. Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.
[10] T. Ley,et al. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Licht,et al. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. , 2003, Best practice & research. Clinical haematology.
[12] Emilie Flaberg,et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells , 2007, Molecular Cancer Therapeutics.
[13] K. Rezvani,et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] A. Madrigal,et al. Transcription factors involved in the regulation of natural killer cell development and function: an update , 2012, Front. Immun..
[15] G. Shurin,et al. ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. , 2012, Current medicinal chemistry.
[16] L. Corcos,et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. , 2001, Cancer research.
[17] L. Bracci,et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.
[18] F. Claas,et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.
[19] Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia , 2005, American journal of hematology.
[20] M. Disis. Immune regulation of cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. Hersh,et al. Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission , 1982, Cancer Immunology, Immunotherapy.
[22] R. Childs,et al. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens , 2015, Nature Reviews Drug Discovery.
[23] R. Nasr,et al. The drug-induced degradation of oncoproteins: an unexpected Achilles' heel of cancer cells? , 2011, Cancer discovery.
[24] A Steinle,et al. NK cells and cancer immunosurveillance , 2008, Oncogene.
[25] I. Weissman,et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .
[26] Rbcafe. The Force Awakens , 2015 .
[27] T. Sayers,et al. Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition1 , 2008, The Journal of Immunology.
[28] G. Fitzgerald,et al. 'I. , 2019, Australian journal of primary health.
[29] Peter Parham,et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. , 2009, Blood.
[30] R. Mesa,et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia , 2005, Leukemia.
[31] C. Kalberer,et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. , 2005, Blood.
[32] Sun-Hee Kim,et al. Induction of NKG2D Ligands and Subsequent Enhancement of NK Cell-mediated Lysis of Cancer Cells by Arsenic Trioxide , 2008, Journal of immunotherapy.
[33] Sharline Madera,et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. , 2012, Immunity.
[34] B. George,et al. Cellular immune reconstitution and its impact on clinical outcome in children with beta thalassemia major undergoing a matched related myeloablative allogeneic bone marrow transplant. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance , 2015, PloS one.
[36] Jian-Hua Tong,et al. Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML , 2010, Science.
[37] R. Oostendorp,et al. TOX2 regulates human natural killer cell development by controlling T-BET expression. , 2014, Blood.
[38] J. Borghans,et al. Immune reconstitution in children following chemotherapy for haematological malignancies: a long‐term follow‐up , 2011, British journal of haematology.
[39] K. Johnson. An Update. , 1984, Journal of food protection.
[40] M. Smyth,et al. Activating and inhibitory receptors of natural killer cells , 2011, Immunology and cell biology.
[41] B. George,et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] B. George,et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. , 2006, Blood.
[43] Benjamin G. Gowen,et al. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection , 2015, Science.
[44] P. Zhang. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. , 1999, Journal of biological regulators and homeostatic agents.
[45] H. Einsele,et al. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells , 2014, Leukemia & lymphoma.
[46] Jessica M Malenfant,et al. CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.
[47] M. Bishop,et al. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[48] M. Waalkes,et al. Arsenic Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1) , 2004, Journal of Biological Chemistry.
[49] C. Niu,et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.
[50] B. George,et al. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience , 2002, American journal of hematology.